Xilio Therapeutics 发布关于Vilastobart的晚期第二阶段数据,适用于MSS mCRC及高血浆肿瘤突变负担患者,在免疫治疗癌症学会(SITC)40周年年会上公布

投资观察
Nov 20, 2025

11月7日(路透社) - Xilio Therapeutics Inc:*XILIO THERAPEUTICS 发布关于Vilastobart的晚期第二阶段数据,适用于MSS mCRC及高血浆肿瘤突变负担患者,在免疫治疗癌症学会(SITC)第40届年会上公布。这些信息源自于发表于2025年11月7日14:05:00.14 GMT的路透社投资者简报。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10